Experiencia en Francia | 18 MAY 15

Directrices terapéuticas sobre ATB en neonatos basadas en evidencias

Los autores analizaron las directrices locales para la terapia antibiótica en todas las unidades de terapia intensiva francesas para evaluar las recomendaciones de dosificación locales actuales.
1
4
Autor/a: Leroux S, Zhao W, Bétrémieux P, Pladys P Arch Dis Child 2015; 100: 394–398
INDICE:  1.  | 2. Referencias
Referencias

1 Marchant EA, Boyce GK, Sadarangani M, et al. Neonatal sepsis due to coagulase-negative staphylococci. Clin Dev Immunol 2013; 2013: 586076.
2 Manzoni P, Rizzollo S, Decembrino L, et al. Recent advances in prevention of sepsis in the premature neonates in NICU. Early Hum Dev 2011; 87:S31–3.
3 Kadambari S, Heath PT, Sharland M, et al. Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units. J Antimicrob Chemother 2011; 66:2647–50.
4 Engle WA. Age terminology during the perinatal period. Pediatrics 2004; 114: 1362–4.
5 Clark RH, Bloom BT, Spitzer AR, et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117:1979–87.
6 Zingg W, Pfister R, Posfay-Barbe KM, et al. Secular trends in antibiotic use among neonates: 2001–2008. Pediatr Infect Dis J 2011; 30:365–70.
7 Zingg W, Posfay-Barbe KM. Antibiotic use in children—off-label use. Curr Drug Targets 2012; 13:885–92.
8 Neubert A, Lukas K, Leis T, et al. Drug utilisation on a preterm and neonatal intensive care unit in Germany: a prospective, cohort-based analysis. Eur J Clin Pharmacol 2010; 66:87–95.
9 Edmond K, Zaidi A. New approaches to preventing, diagnosing, and treating neonatal sepsis. PLoS Med 2010; 7: e1000213.
10 Lutsar I, Metsvaht T. Understanding pharmacokinetics pharmacodynamics in managing neonatal sepsis. Curr Opin Infect Dis 2010; 23: 201–7.
11 http://www.eucast.org
12 http://www.clsi.org
13 Asín E, Isla A, Canut A, et al. Comparison of antimicrobial pharmacokinetic/ pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria. Int J Antimicrob Agents 2012; 40:313–22.
14 Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int J Pharm 2013; 16:8–13.
15 Guidance for industry: exposure–response relationships—study design, data analysis, and regulatory applications. http://www.fda.gov/downloads/Drugs
16 European Medicines Agency. Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products. Ref.CPMP/EWP/2655/99). http://www.ema.europa.eu
17 European Medicines Agency. Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 1). http://www.ema.europa.eu
18 Setiabudy R, Suwento R, Rundjan L, et al. Lack of a relationship between the serum concentration of aminoglycosides and ototoxicity in neonates. Int J Clin Pharmacol Ther 2013; 51:401–6.
19 De Cock RFW, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012; 51:105–17.
20 Abdel-Hady E, El Hamamsy M, Hedaya M, et al. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther 2011; 36:45–52.
21 Schreuder MF, Wilhelm AJ, Bökenkamp A, et al. Impact of gestational age and birth weight on amikacin clearance on day 1 of life. Clin J Am Soc Nephrol 2009; 4:1774–8.
22 Siddiqi A, Khan DA, Khan FA, et al. Therapeutic drug monitoring of amikacin in preterm and term infants. Singapore Med J 2009; 50:486–9.
23 Sherwin CMT, Svahn S, Van der Linden A, et al. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol 2009; 65:705–13.
24 Allegaert K, Anderson BJ, van den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit 2007; 29:284–91.
25 Allegaert K, Cossey V, Debeer A, et al. The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. Pediatr Nephrol 2005; 20:740–3.
26 Tréluyer JM, Merlé Y, Tonnelier S, et al. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother 2002; 46:1381–7.
27 Labaune JM, Bleyzac N, Maire P, et al. Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models. Biol Neonate 2001; 80:142–7.
28 Wang J, Liang WQ, Wu JJ, et al. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method. Acta Pharmacol Sin 2000; 21:954–60.
29 Langhendries JP, Battisti O, Bertrand JM, et al. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 1998; 74:351–62.
30 Botha JH, du Preez MJ, Miller R, et al. Determination of population pharmacokinetic parameters for amikacin in neonates using mixed-effect models. Eur J Clin Pharmacol 1998; 53:337–41.
31 Petersen PO, Wells TG, Kearns GL. Amikacin dosing in neonates: evaluation of a dosing chart based on population pharmacokinetic data. Dev Pharmacol Ther 1991; 16:203–11.
32 Kenyon CF, Knoppert DC, Lee SK, et al. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 1990; 34:265–8.
33 Admiraal R, van Kesteren C, Boelens JJ, et al. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child 2014; 99:267–72.
34 Jacqz-Aigrain E, Zhao W, Sharland M, et al. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 2013; 18:28–34.
35 Cohen-Wolkowiez M, Ouellet D, Smith PB, et al. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother 2012; 56:1828–37.
36 Suyagh M, Collier PS, Millership JS, et al. Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics 2011; 127:e367–374.
37 Pandolfini C1, Kaguelidou F, Sequi M, et al. Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections. Eur J Clin Pharmacol 2013;69:1031–6.
38 NICE Clinical Guidence: Antibiotics for early-onset neonatal infection. 2012.
39 Porta A, Hsia Y, Doerholt K, et al. Comparing neonatal and paediatric antibiotic prescribing between hospitals: a new algorithm to help international benchmarking. J Antimicrob Chemother 2012; 67:1278–86.
40 Neofax. Thomson Reuters Clinical Editorial Staff. 2011.
41 RedBook. American Academy of Pediatrics. 2013.
42 Kaguelidou F, Turner MA, Choonara I, et al. Randomized controlled trials of antibiotics for neonatal infections: a systematic review. Br J Clin Pharmacol 2013; 76:21–9.
43 Pansieri C, Bonati M, Choonara I, et al. Neonatal drug trials: impact of EU and US paediatric regulations. Arch Dis Child Fetal Neonatal Ed 2014; 99:F438.
44 Benjamin DK Jr, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006; 296:1266–73.
45 Nicklin S, Spencer SA. Recruitment failure in early neonatal research. Arch Dis Child Fetal Neonatal Ed 2004; 89:F281.
46 Amiel P, Moreau D, Vincent-Genod C, et al. Noninvitation of eligible individuals to participate in pediatric studies: a qualitative study. Arch Pediatr Adolesc Med 2007; 161:446–50.
 

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2020